We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GeneDx Partners With Komodo Health to Advance Rare Disease Research
Read MoreHide Full Article
Key Takeaways
GeneDx partnered with Komodo Health to link the Infinity platform with real-world patient data.
WGS expands data monetization by enabling HEOR, biopharma development and AI-driven analytics.
GeneDx gains a longitudinal view of rare diseases by pairing genomics with claims-based care patterns.
GeneDx Holdings (WGS - Free Report) recently announced a strategic partnership with Komodo Health that is likely to combine its Infinity platform with real-world patient insights from Komodo’s Healthcare Map, creating a more complete longitudinal view of rare diseases. The collaboration links GeneDx’s genomic and phenotypic data with real-world care patterns, helping illuminate how rare disease patients are diagnosed, treated and managed over time.
From an investor standpoint, this partnership meaningfully expands the utility and monetization potential of GeneDx’s data assets. By enabling stronger health economics research, faster biopharma development and AI-driven analytics, the deal reinforces GeneDx’s positioning as a key data and insights partner in the rare disease market.
Likely Trend of WGS Stock Following the News
Following the announcement, shares of the company traded flat in the after-market trading session on Friday. However, in the last six-month period, WGS’s shares have surged 64.3% compared with the industry’s 12.7% growth. The S&P 500 increased 14.1% in the same time frame.
Over the long term, this partnership is likely to help GeneDx turn its large genomic database into a more powerful and commercially valuable platform. By linking genetic data with real-world patient outcomes and healthcare usage, GeneDx can better support drug discovery, clinical trials and payer discussions, making its services more attractive to biopharma companies. This deeper integration into the rare disease ecosystem can lead to more recurring partnerships, higher-value contracts and a stronger competitive moat, supporting more durable revenue growth over time.
Meanwhile, WGS currently has a market capitalization of $3.91 billion.
Image Source: Zacks Investment Research
More on the Partnership News
GeneDx’s Infinity platform sits at the center of this collaboration, bringing together more than 25 years of genomic expertise, over 2.5 million genetic tests, and millions of phenotypic data points across a highly diverse patient base. What makes this partnership incremental is the linkage of Infinity with Komodo Health’s Healthcare Map, which tracks longitudinal healthcare journeys of more than 330 million de-identified patients across Medicare, Medicaid, and commercial insurance. By connecting genomics with claims-based data such as diagnoses, procedures, encounters, and estimated costs, GeneDx can move beyond genetic answers to show how rare disease patients actually interact with the healthcare system over time.
The combined dataset is designed to support high-impact real-world evidence use cases that matter to biopharma and healthcare decision-makers. This includes Health Economics and Outcomes Research, where companies can better quantify disease burden, diagnostic delays, unmet needs and real-world treatment impact. On the R&D side, linking genetic insights with real-world care patterns can improve target identification, natural history studies and patient stratification—critical areas in rare disease drug development where data gaps are common.
The partnership also has meaningful implications for clinical trials, market access and advanced analytics. Biopharma companies can use the integrated data to identify trial cohorts faster, assess feasibility more accurately, and even build external control arms for rare disease studies.
Favorable Industry Prospects for WGS
Per a report by Grand View Research, the global rare diseases treatment market size was estimated at $216.24 billion in 2024 and is projected to reach $374.39 billion by 2030, expanding at a CAGR of 11.6% from 2025 to 2030.
Other Recent Developments of WGS
GeneDx recently launched GenomeDx Prenatal, a whole-genome sequencing test aimed at providing faster and more definitive genetic answers during high-risk pregnancies. Designed for cases where fetal anomalies are detected on ultrasound, the test uses a phenotype-informed, trio-based approach to deliver clear, actionable insights with rapid turnaround times, highlighting GeneDx’s continued focus on expanding its clinical impact across critical care settings.
WGS’s Zacks Rank & Stocks to Consider
WGS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted earnings per share (EPS) of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2, reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GeneDx Partners With Komodo Health to Advance Rare Disease Research
Key Takeaways
GeneDx Holdings (WGS - Free Report) recently announced a strategic partnership with Komodo Health that is likely to combine its Infinity platform with real-world patient insights from Komodo’s Healthcare Map, creating a more complete longitudinal view of rare diseases. The collaboration links GeneDx’s genomic and phenotypic data with real-world care patterns, helping illuminate how rare disease patients are diagnosed, treated and managed over time.
From an investor standpoint, this partnership meaningfully expands the utility and monetization potential of GeneDx’s data assets. By enabling stronger health economics research, faster biopharma development and AI-driven analytics, the deal reinforces GeneDx’s positioning as a key data and insights partner in the rare disease market.
Likely Trend of WGS Stock Following the News
Following the announcement, shares of the company traded flat in the after-market trading session on Friday. However, in the last six-month period, WGS’s shares have surged 64.3% compared with the industry’s 12.7% growth. The S&P 500 increased 14.1% in the same time frame.
Over the long term, this partnership is likely to help GeneDx turn its large genomic database into a more powerful and commercially valuable platform. By linking genetic data with real-world patient outcomes and healthcare usage, GeneDx can better support drug discovery, clinical trials and payer discussions, making its services more attractive to biopharma companies. This deeper integration into the rare disease ecosystem can lead to more recurring partnerships, higher-value contracts and a stronger competitive moat, supporting more durable revenue growth over time.
Meanwhile, WGS currently has a market capitalization of $3.91 billion.
Image Source: Zacks Investment Research
More on the Partnership News
GeneDx’s Infinity platform sits at the center of this collaboration, bringing together more than 25 years of genomic expertise, over 2.5 million genetic tests, and millions of phenotypic data points across a highly diverse patient base. What makes this partnership incremental is the linkage of Infinity with Komodo Health’s Healthcare Map, which tracks longitudinal healthcare journeys of more than 330 million de-identified patients across Medicare, Medicaid, and commercial insurance. By connecting genomics with claims-based data such as diagnoses, procedures, encounters, and estimated costs, GeneDx can move beyond genetic answers to show how rare disease patients actually interact with the healthcare system over time.
The combined dataset is designed to support high-impact real-world evidence use cases that matter to biopharma and healthcare decision-makers. This includes Health Economics and Outcomes Research, where companies can better quantify disease burden, diagnostic delays, unmet needs and real-world treatment impact. On the R&D side, linking genetic insights with real-world care patterns can improve target identification, natural history studies and patient stratification—critical areas in rare disease drug development where data gaps are common.
The partnership also has meaningful implications for clinical trials, market access and advanced analytics. Biopharma companies can use the integrated data to identify trial cohorts faster, assess feasibility more accurately, and even build external control arms for rare disease studies.
Favorable Industry Prospects for WGS
Per a report by Grand View Research, the global rare diseases treatment market size was estimated at $216.24 billion in 2024 and is projected to reach $374.39 billion by 2030, expanding at a CAGR of 11.6% from 2025 to 2030.
Other Recent Developments of WGS
GeneDx recently launched GenomeDx Prenatal, a whole-genome sequencing test aimed at providing faster and more definitive genetic answers during high-risk pregnancies. Designed for cases where fetal anomalies are detected on ultrasound, the test uses a phenotype-informed, trio-based approach to deliver clear, actionable insights with rapid turnaround times, highlighting GeneDx’s continued focus on expanding its clinical impact across critical care settings.
WGS’s Zacks Rank & Stocks to Consider
WGS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted earnings per share (EPS) of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2, reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.